Tissue Genesis, Inc., a pioneering entity in the regenerative medicine sector, is headquartered in the United States. Founded in 2006, the company has established itself as a leader in the development of innovative tissue engineering solutions, particularly in the fields of cellular therapies and regenerative medicine. With a focus on harnessing the potential of adipose-derived stem cells, Tissue Genesis offers unique products and services that facilitate advanced healing and tissue regeneration. Their proprietary technologies are designed to enhance patient outcomes in various medical applications, setting them apart in a competitive market. Recognised for their commitment to quality and innovation, Tissue Genesis continues to expand its operational reach, contributing significantly to the advancement of regenerative therapies and solidifying its position as a key player in the industry.
How does Tissue Genesis, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Tissue Genesis, Inc.'s score of 23 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Tissue Genesis, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Tissue Genesis, Inc. may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. Without emissions data or reduction initiatives, it is challenging to assess the company's environmental impact or its alignment with industry standards for climate action.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Tissue Genesis, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
